Your account is not claimed yet. You can sign up with ORCID to claim your account.

Per Nilsson

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Top Venues

Acta oncologica (Stockholm, Sweden)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Skånes universitetssjukhus Lund

Lund University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Skånes universitetssjukhus Lund Oct 1o 1985

Sweden

Assoc. Prof., Mdical Physicist :: Department of Hematology, Oncology and Radiation Physics

Education History

Lund University Sep 1o 1975

Sweden

PHD :: Department of Radiation Physics

Publications

Tiago M Bonde, Hans Garmo, Pär Stattin, Per Nilsson, Adalsteinn Gunnlaugsson, Daniela Swanberg, David Robinson
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta oncologica (Stockholm, Sweden) (2023)
Gabriel Adrian, Maria Gebre-Medhin, Per Nilsson
Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors. Acta oncologica (Stockholm, Sweden) (2023)
Maria Gebre-Medhin, Eva Brun, Per Engström, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjödin, Henrik Carlsson, Karin Söderkvist, Marcus Thomasson, Björn Zackrisson, Per Nilsson
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (1) (2020)
Gabriel Adrian, Maria Gebre-Medhin, Elisabeth Kjellén, Elinore Wieslander, Björn Zackrisson, Per Nilsson
Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN-trial. Head & neck 42 (8) (2020)